Evidence map›Paper›PMID 33062675›Full record

ArticleBioMed research international2020

Xiaolan Pan, Meiqin Li, Lei Huang, Dan Mo, Yihua Liang, Zhaodong Huang, Bo Zhu, Min Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. The Influence of Genetic Polymorphisms ofInternational journal of dentistry · 2025
    Article
  3. Review
  4. Macrophages and cancer stem cells: a malevolent alliance.Molecular medicine (Cambridge, Mass.) · 2021
    Review
  5. ACancers · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaolan PanDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.
Meiqin LiDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.
Lei HuangDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.
Dan MoDepartment of Surgery, Maternal and Child Health Hospital of the Guangxi Zhuang Autonomous Region, Nanning, China.
Yihua LiangDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.
Zhaodong HuangDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.
Bo ZhuDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.
Min FangDepartment of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021 Guangxi, China.ORCID https://orcid.org/0000-0001-6343-9908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interleukin- (IL-) 33/

Indexed as

AdolescentAdultAgedAged, 80 and overAsian PeopleBiomarkers, TumorCarcinoma, HepatocellularChildChinaCohort StudiesFemaleGenetic Predisposition to DiseaseHumansHyaluronan ReceptorsInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Biomarkers, TumorCD44 protein, humanHyaluronan ReceptorsIL1RL1 protein, humanIL33 protein, humanInterleukin-1 Receptor-Like 1 ProteinInterleukin-33

Identifiers

PMID33062675
PMCPMC7538256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.